Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-09-02
2010-06-29
Landsman, Robert (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C530S388150, C530S388220, C530S388230, C530S389100, C530S389200, C530S391300, C424S130100, C424S138100, C424S139100
Reexamination Certificate
active
07745585
ABSTRACT:
The functional characterization of ILEI to be a novel cytokine involved in epithelial/mesenchymal transition and the identification of biologically active ILEI provides the basis for generating ILEI inhibitors, in particular anti-ILEI antibodies, that are useful in the therapy of cancer, fibrosis and COPD.
REFERENCES:
patent: 6506607 (2003-01-01), Shyjan
patent: 6566078 (2003-05-01), Raitano et al.
patent: 6902911 (2005-06-01), Conklin et al.
patent: 2004/0137575 (2004-07-01), Conklin
patent: WO 99/25828 (1999-05-01), None
patent: WO 99/47658 (1999-09-01), None
patent: WO 99/56778 (1999-11-01), None
patent: WO 02/063009 (2002-08-01), None
Zhu, Y. et al; “Cloning, Expression, and Initial Characterization of a Novel Cytokine-like Gene Family”; Genomics, vol. 80, No. 2, 2002; pp. 144-150.
Ohno, I. et al; “The cloning of a cDNA for novel genes expressed in human osteoblasts”; 1998; XP002230218; Database Accession No. D87120.
Strausberg, R. L. et al; “Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences”; 2001; XP002269510; Database Accession No. BC009086.
Arnon, et al; “Monoclonal Antibodies For Immunotargeting of Drugs In Cancer Therapy”, Monoclonal Antibodies and Cancer Therapy, Reisfeld, et al (eds.)(1985), pp. 243-256.
Baldwin, et al; “Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy”, Academic Press (1985), pp. 303-316.
Bartel, et al; “Isolation of New Ribozymes from a Large Pool of Random Sequnces” (1993) Science 261; pp. 1411-1418.
Bauer, M., et al , “TGFbeta1 in liver fibrosis; time to change paradigms?” FEBS Letters (2001) 502, pp. 1-3.
Beddington, R.S., et al , “Axis development and early asymmetry in mammals.” (1999), Cell, 96(2); pp. 195-209.
Beidler, et al., “Cloning and High Level Expression of a Chimeric Antibody With Specificity for Human Carcinoembryonic Antigen”; J Immunol (1988), 141: pp. 4053-4060.
Bernstein, et al.; “Role for a bidentate ribonuclease in the initiation step of RNA interference”; Nature (2001), 409, p. 363.
Better, et al.; “Escherichia coliSecretion of an Active Chimeric Antibody Fragment”; Science (1988), 240; pp. 1041-1043.
Boyer, B., et al., “Induction and regulation of epithelial-mesenchymal transitions”; Biochem Pharmacol (2000), 60 (8); pp. 1091-1099.
Bromberg, J., “Stat proteins and oncogenesis”; J Clin Invest (2002), 109 (9); pp. 1139-1142.
Chang,G. D., et al; “Improvement of glycosylation in insect cells with mammalian glycosyltransferases”; Journal of Biotechnology (2003) 102, pp. 61-71.
Christofori, G., et al, “The role of the cell-adhesion molecule E-cadherin as a tumor-suppressor gene”; Trends Biochem Sci 24(2); pp. 73-76, (1999).
Ciruna, B., et al, “FGF signaling regulates mesoderm cell fate specification and morphogenetic movement at the primitive streak”; Dev. Cell, (2001) 1(1); pp. 37-49.
Coker, R.K., et al, “Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung”; Thorax (2001) 56(7); pp. 549-556.
Coussens, L. M., et al , “Inflammation and cancer.” Nature (2002) 420 (6917); pp. 860-867.
De Wever, O., et al; “Role of myofibroblasts at the invasion front”; Biol Chem, (2002), 383(1); pp. 55-67.
Dillmann, R. O.; “Perceptions of Herceptin : a monoclonal antibody for the treatment of breast cancer”; Cancer Biother. Radiopharm. (1999) 14; pp. 5-10.
Ding H., et al; “A Mice with Cre recombinase activatable PDGF-C expression” Genesis Feb; (2002) 32 (2); pp. 181-183.
Duband, J.L., et al; “Epithelium-mesenchyme transition during neural crest development”; Acta. Anat., (1995), 154(1); pp. 63-78.
Ellenrieder, V., et al., “Invasion and metastasis in pancreatic cancer.” Ann Oncol, (1999), 10 Suppl 4; pp. 46-50.
Emini, E. A., et al; “Induction of Hepatitis A Virus-Neutralizing Antibody by a Virus-Specific Synthetic Peptide”; J Virology (1985), 55, pp. 836-839.
Fidler, I. J., et al, “Biologic diversity in metastatic neoplasms-origins and implications”; Science, (1982) 217; pp. 998-1001.
Fidler, I. J., “The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited”; Nat Rev Cancer (2003), 3(6); pp. 453-458.
Figini, M. et al., “Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection”; Cancer Res. (1998) 58; pp. 991-996.
Fire, A. et al., “Potent and specific genetic interference by double-stranded RNA inCaenorhabditis elegans” ; Nature (1998), 391; pp. 806-811.
Frey et al., “Epidermal Growth Factor-stimulated intestinal epithelial cell migration requires Src family kinase-dependent p38 MAPK signaling”; J Biol Chem. (2004), 279 (42); pp. 44513-44521.
Joseph, G. et al; “‘Peptide Walking’ Is a Novel Method for Mapping Functional Domains in Proteins”; Biol Chem.; vol. 270, No. 49, (1995), pp. 29079-29082.
Goding, “Monoclonal Antibodies: Principles and Practice”; Academic Press (1986), pp. 59-103.
Gonzalez-Rothi, R.J.,et al, “Effects of low-yield-cigarette smoke inhalation on rat lung macrophages”; J Toxicol Environ Health, (1986), 17(2-3); pp. 221-228.
Goumenos, D.S., et al., “Apoptosis and myofibroblast expression in human glomerular disease: a possible link with transforming growth factor-beta-1”; Nephron, (2002), 92(2); pp. 287-296.
Grunert, S., et al; “Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis”; Nat Rev Mol Biol (2003) 4(8); pp. 657-665.
Hanahan, D., et al ; “Less is more regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice”; J Clin Invest (2000) 105 (8); pp. 1045-1047.
Hanahan, D., et al; “The hallmarks of cancer”; Cell (2000) 100(1); pp. 57-70.
Haseloff J., et al; “Simple RNA enzymes with new and highly specific endoribonuclease activities”; Nature (1988) 334; pp. 585-591.
Hay, E. D.; “An overview of epithelio-mesenchymal transformation”; Acta Anat (Basel) (1995) 154(1); pp. 8-20.
Hay E. D., et al, “Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced”; Am J Kidney Dis (1995) 26(4); pp. 678-690.
Heider, K., et al; “A Human Homologue of the Rat Metastasis-associated Variant of CD44 Is Expressed in Colorectal Carcinomas and Adenomatous Polyps”; J Cell Biol (1993) 120(1); pp. 227-233
Hellstrom,K. E. et al; “Antibodies for Drug Delivery”, Controlled Drug Delivery (2nd Ed.), Robinson et al. (eds.) (1987), pp. 623-653 (Marcel Dekker, Inc.).
Holgate, S.T., “Epithelial damage and response”; Clin Exp Allergy, 30 Suppl (2000) 1; pp. 37-41.
Janda, E. et al; “Ras and TGFBeta cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways”; J Cell Biol, Jan. 21, 2002, 156 (2); pp. 299-313.
Janda, E., et al; “Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway”; Oncogene (2002), 33; pp. 5148-5159.
Jameson, B.A., et al; “The antigenic index: a noval algorithm for predicting antigenic determinants”; Comput Appl Biosci (1988) 4, pp. 181-186.
Jespers, L. S., et al.; “Guiding the Selection of Human Anitbodies from Phage Display Repertoires to a Single Epitope of an Antigen”; Bio/Technology (1994), 12; pp. 899-903.
Jones, P. T., et al; “Replacing the complementarity-determining regions in a human antibody with those from a mouse”; Nature (1986) 321; pp. 552-525.
Kyte, J., et al; “A simple method fo
Ahorn Horst Johann
Beug Hartmut
Gruenert Stefan
Heider Karl-Heinz
Jechlinger Martin
Boehringer Ingelheim International GmbH
Devlin Mary-Ellen M.
Landsman Robert
Morris Michael P.
Petka Wendy A.
LandOfFree
Antibodies to interleukin-like epithelial-mesenchymal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies to interleukin-like epithelial-mesenchymal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies to interleukin-like epithelial-mesenchymal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4196273